Chinese Ioversol Market Outlook to 2022: Featuring Jiangsu Hengrui Medicine, Liebel-Flarsheim and Mallinckrod –

The “Investigation
Report on Chinese Ioversol Market, 2018-2022” report has been
added to’s offering.

Contract media are chemical products that are injected into or taken by
human tissues or organs to improve image observation. The global
contrast media market is growing continuously with higher demand for
medical exam accuracy and increasing popularity of angiography

Ioversol is a new-type non-ionic contrast agent mainly used in
contrast-enhanced vascular imaging, featured by high contract density,
avirulence, high tolerance and few side effects. After Ioversol is
injected to blood vessels, the high proportion of iodine can cause x-ray
attenuation and clearly shows the blood vessels till Ioversol is diluted.

Contrast media are among the most common drugs in interventional
radiology practice. They are mainly used to show blood vessels and
coeloms. With large growth momentum and potential, the applications of
contrast media has gradually extended from x-ray photography/CT scan
imaging to diagnoses and examinations such as ultrasonography and
magnetic resonance angiography. Ioversol has been widely used in China.
As the number of the diagnosed continues to rise, the Ioversol market
will continue to grow in China.

With China’s growing demand for Ioversol, the sales value exceeded CNY
400 million in 2017. According to the researcher, Jiangsu Hengrui,
Liebel-Flarsheim and Mallinckrodt accounted for the major shares of the
Chinese Ioversol market. By sales value, the market share of Jiangsu
Hengrui exceeded 90% in 2017.

Companies Featured

Key Topics Covered

1 Relevant Concepts of Ioversol

2 Investigation on Sales of Ioversol in China, 2013-2017

3 Investigation on Market Share of Major Ioversol Manufacturers in
China, 2013-2017

4 Prospects of Chinese Ioversol Market, 2018-2022

Selected Charts

For more information about this report visit

View source version on

Leave a Comment